Screener
Denali Therapeutics Inc. DNLI Business Segments — SG&A
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Denali Therapeutics Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:08 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001714899-26-000097
| Line item | Therapeutics Segment / Three Months Ended June 30, 2026 | Therapeutics Segment / Three Months Ended June 30, 2025 | Therapeutics Segment / Six Months Ended June 30, 2026 | Therapeutics Segment / Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total research and development expenses | 97,019 | 102,696 | 200,865 | 218,923 |
| Personnel related selling, general and administrative expenses | 22,921 | 20,115 | 45,485 | 38,853 |
| Other selling, general and administrative expenses | 13,362 | 12,152 | 24,309 | 22,767 |
| Total selling, general and administrative expenses | 36,283 | 32,267 | 69,794 | 61,620 |
| Intangible asset amortization | $750 | — | $750 | — |
| Segment operating expenses | 134,145 | 134,963 | 271,502 | 280,543 |
| Segment loss from operations | (130,541) | (134,963) | (267,898) | (280,543) |
| Segment interest and other income, net | 2,988 | 10,844 | 11,898 | 23,454 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Denali Therapeutics Inc.'s business segments — SG&A?
- Denali Therapeutics Inc. (DNLI) reported business segments — SG&A of $36.28M in Q2 2026.
- What does business segments — SG&A mean?
- This metric represents the aggregate selling, general, and administrative expenses attributable to the therapeutics business segment, encompassing both personnel and non-personnel operational costs. It serves as a comprehensive measure of the overhead required to support the company's core drug discovery and development programs. Investors use this figure to gauge the overall administrative burden and operational leverage inherent in the company's therapeutic development strategy.
Ask your AI about Denali Therapeutics Inc.'s business segments — sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude